Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06036121 · ClinicalTrials.gov registry record · Phase 1
A Study of ADRX-0706 in Select Advanced Solid Tumors
A Phase 1 study of Cervical Cancer and Solid Tumors, sponsored by Adcentrx Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT06036121 is a Phase 1 study of Cervical Cancer and Solid Tumors that is active but no longer recruiting, run by Adcentrx Therapeutics. The registered enrollment target is 144 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT06036121, a Phase 1 study of Cervical Cancer and Solid Tumors, is active but no longer recruiting, sponsored by Adcentrx Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
Conditions Studied
Interventions
- DRUG ADRX-0706
Study Locations (20)
Other
- Beijing University Third Hospital - Beijing
- Fujian Cancer Hospital - Fujian
- Sun Yat-sen University Cancer Center - Guangzhou
- Hunan Cancer hospital - Hunan
- Shandong Cancer Hospital - Jinan
- Shanghai East Hospital - Shanghai
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
Michigan
- Karmanos Cancer Institute - Detroit
- Henry Ford Cancer - Detroit
- START Midwest - Grand Rapids
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- UCLA - Los Angeles
Florida
- Comprehensive Hematology Oncology - St. Petersburg
- Moffitt Cancer Center - Tampa
Texas
- University of Texas MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
Ohio
- The Ohio State University Wexner Medical Center - Hilliard
Oklahoma
- Stephenson Cancer Center - Oklahoma City
Tennessee
- Sarah Cannon Cancer Network - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06036121
The ClinicalTrials.gov registry entry for NCT06036121 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Adcentrx Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which ADRX-0706 is the first listed.
NCT06036121 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT06036121 about?
NCT06036121 is a clinical study titled "A Study of ADRX-0706 in Select Advanced Solid Tumors". The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
What is the current status of trial NCT06036121?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2023-09-26. Estimated completion is 2026-12.
What conditions does trial NCT06036121 study?
This clinical trial studies the following conditions: Cervical Cancer, Solid Tumors, Urothelial Cancer, Triple Negative Breast Cancer (TNBC).
What interventions are being tested in trial NCT06036121?
The interventions under investigation include: ADRX-0706 (DRUG).
Who is sponsoring clinical trial NCT06036121?
This trial is sponsored by Adcentrx Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06036121 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.